Archives
-
Verapamil HCl: Workflows for Calcium Signaling
2026-08-25
Verapamil HCl enables controlled L-type calcium channel perturbation across calcium flux, myeloma apoptosis, inflammatory signaling, and bone-remodeling assays. This workflow-focused guide connects acute channel inhibition with the newer Txnip-centered osteoporosis findings while emphasizing controls, assay timing, and troubleshooting.
-
Tetraethylammonium Chloride: Causal Assay Design
2026-08-25
Tetraethylammonium chloride (TEAC) is more than a generic potassium-channel inhibitor: it can serve as a mechanistic perturbation for testing pore access, electrical current, and downstream physiology. This article translates classic K+-channel methodology into a decision framework for electrophysiology, vascular, autonomic, and secretory research.
-
PDX1 Mutations, Pancreatic Agenesis, and m6A
2026-08-24
Zhang et al. established PDX1-mutant cynomolgus macaques to model pancreatic agenesis and MODY4-associated developmental defects in a primate context. Their integration of RNA sequencing, m6A analysis, islet organoids, and METTL3 rescue identifies altered m6A regulation as a potentially important layer of PDX1-linked pancreatic dysfunction.
-
(+)-Bicuculline: Protocol and QC Guide
2026-08-24
(+)-Bicuculline (SKU N1592) provides a practical way to probe GABAA-mediated inhibitory signaling in neuronal assays while assessing related changes in synaptic NMDA receptor signaling. It is intended for controlled scientific research only, not for diagnostic, therapeutic, or clinical use, and its insolubility in water and ethanol requires disciplined DMSO-based formulation and quality control.
-
BHQ for Calcium Signaling Research
2026-08-23
BHQ creates a controlled SERCA-dependent disturbance that links ER calcium-store depletion to live-cell signaling, vascular physiology, and hematopoietic stem cell assays. This guide emphasizes practical workflow design, assay controls, and troubleshooting rather than treating BHQ as a universal ER-stress reagent.
-
ML365, NLRP3, and Cognitive Impairment After Surgery
2026-08-22
A 2024 Brain Research study tested ML365 in aged mice undergoing exploratory laparotomy and found improved postoperative cognition alongside reduced hippocampal NLRP3 inflammasome signaling and systemic oxidative stress. The work extends K2P channel pharmacology into postoperative neuroinflammation, while leaving direct TASK1 target engagement and clinical relevance unresolved.
-
ML133 HCl for Kir2.1 Assay Workflows
2026-08-22
ML133 HCl is a selective potassium channel inhibitor for connecting Kir2.1 activity with potassium ion transport, PASMC behavior, and vascular remodeling. This practical guide translates published PASMC experiments into controlled dosing, orthogonal readouts, and troubleshooting strategies for cardiovascular ion channel research.
-
DIDS: A Causal Lens on Cell-Death Biology
2026-08-21
DIDS is more than a chloride transport probe: it can help dissect how cells surviving impending death acquire prometastatic properties. This article connects DIDS mechanism, assay design, and the PAME study while defining the controls needed for interpretable results.
-
BHQ Workflows for SERCA and Calcium Signaling
2026-08-20
Build reproducible calcium-store depletion, vascular smooth muscle, and hematopoietic stem cell assays with BHQ, a mechanistically focused SERCA perturbagen. This guide pairs practical concentration, timing, control, and troubleshooting strategies with the CaMKII–STAT3–CXCR4 findings reported in recent HSC research.
-
TBXA2R–ERM Signaling Drives TNBC Metastasis
2026-08-20
Leguay and colleagues identify TBXA2R as a GPCR that activates ezrin, radixin, and moesin through Gαq/11, Gα12/13, Rho GTPases, and the kinases SLK and LOK. The study connects this signaling axis to triple-negative breast cancer cell motility, invasion, and metastatic colonization, providing a mechanistic framework for studying cytoskeletal control of metastasis.
-
Propranolol Workflows for Translational Research
2026-08-19
Build reproducible Propranolol assays across cardiovascular regulation, tremor biology, emotional memory modulation, and metabolic signaling. This workflow-led guide combines solvent planning, paired functional readouts, and TMS-informed assay design to distinguish peripheral β-blockade from central circuit effects.
-
Simvastatin: Membrane-State-Aware Research
2026-08-19
Simvastatin (Zocor) is more than an HMG-CoA reductase inhibitor: its lactone-to-acid conversion and membrane localization can shape experimental outcomes. This guide translates membrane-biophysics findings into practical assay design for lipid metabolism and hepatic cancer research.
-
Pyridostigmine, α-Bungarotoxin, and Placental Necroptosis
2026-08-18
The reference study identifies placental necroptosis as a pharmacologically tractable component of preeclampsia-like pathology in reduced uterine perfusion pressure rats. By combining pyridostigmine treatment with α7 nicotinic acetylcholine receptor antagonism, necroptosis inhibition, human placental analysis, and hypoxic trophoblast experiments, it links non-neuronal cholinergic signaling to placental inflammation and vascular dysfunction.
-
GS967: Cardiac Late Sodium Current Inhibitor
2026-08-18
GS967 enables targeted suppression of pathological late Na+ influx for in vitro cardiac electrophysiology, ventricular myocyte studies, and ex vivo arrhythmia models. Its potency, voltage-dependent activity, and limited use-dependence make it useful for separating late-current mechanisms from broader conduction effects.
-
ω-Agatoxin IVA TFA: A Precision Cav2.1 Lens
2026-08-17
ω-Agatoxin IVA TFA is a selective Cav2.1 probe that connects channel biophysics with synaptic release, seizure biology, and neuroprotection research. This thought-leadership guide explains how to deploy omega-agatoxin IVA strategically, interpret subtype-dependent potency, and avoid overextending preclinical findings toward therapeutic conclusions.